It’s late. The lab is quiet, except for that one dataset everyone’s staring at. You’ve just seen something real. A molecule that’s hitting hard across cancer cell line models. Clean biology. Strong IC50 values. Even the in vivo data looks promising. For a moment, it feels like this might be it. Fast-forward two years. The program is nowhere. No clear path forward. No partner. No momentum. Just another asset that couldn’t cross the line, buried in the infamous “Valley of Death